• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail
-

Search Publications



Fields



Centers











Starting Date


Ending Date


Order by

Entry Details

J Pharm Sci 2017 Oct;106(10):2930-45

Biowaiver monograph for immediate release solid oral dosage forms: amoxicillin trihydrate.

Thambavita D, Galappatthy P, Mannapperuma U, Jayakody RL, Cristofoletti R, Abrahamsson B, Groot DW, Langguth P, Mehta M, Parr A, Polli JE, Shah VP, Dressman J

Abstract

Literature and experimental data relevant to waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing amoxicillin trihydrate are reviewed. Solubility and permeability characteristics according to the Biopharmaceutics Classification System (BCS), therapeutic uses, therapeutic index, excipient interactions, as well as dissolution and BE/bioavailability (BA) studies were taken into consideration. Solubility and permeability studies indicate that amoxicillin doses up to 875mg belong to BCS class I, while 1000 mg belongs to BCS class II and doses above 1000mg belong to BCS class IV. Considering all aspects, the biowaiver procedure can be recommended for solid oral products of amoxicillin trihydrate immediate release preparations containing amoxicillin as the single Active Pharmaceutical Ingredient (API) at dose strengths of 875mg or less, provided (a) only the excipients listed in this monograph are used, and only in their usual amounts, (b) the biowaiver study is performed according to the WHO, FDA or EMA recommended method using the innovator as the comparator, and (c) results comply with criteria for "very rapidly dissolving" or "similarly rapidly dissolving". Products containing other excipients, and those containing more than 875mg amoxicillin per unit should be subjected to an in vivo BE study.


Category: Journal Article, Editorial
PubMed ID: #28483422 DOI: 10.1016/j.xphs.2017.04.068
Includes FDA Authors from Scientific Area(s): Drugs
Entry Created: 2017-05-11 Entry Last Modified: 2017-12-24
Feedback
-
-